|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.300 USD | -5.29% |
|
-0.46% | +167.08% |
| 07-09 | Macrogenics, Inc. Announces Resignation of Karen Ferrante from Director Role, Effective September 1, 2026 | CI |
| 07-02 | MacroGenics Closes Sale of Manufacturing Operations to Bora Pharmaceuticals | MT |
Company Valuation: MacroGenics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 983.2 | 412.5 | 596.7 | 204 | 101.8 | 273.3 | - | - |
| Change | - | -58.04% | 44.66% | -65.82% | -50.07% | 168.37% | - | - |
| Enterprise Value (EV) | 983.2 | 412.5 | 366.9 | 204 | 101.8 | 273.3 | 273.3 | 273.3 |
| Change | - | -58.04% | -11.05% | -44.41% | -50.07% | 168.37% | 0% | 0% |
| P/E | -4.76x | -3.44x | -64.1x | -3.04x | -1.36x | -6.41x | -2.81x | -2.17x |
| PBR | - | - | - | - | - | - | - | - |
| PEG | - | 0.1x | 0.7x | -0x | -0.1x | 0.1x | -0x | -0.1x |
| Capitalization / Revenue | 12.7x | 2.71x | 10.2x | 1.36x | 0.68x | 1.66x | 2.9x | 2.02x |
| EV / Revenue | 0x | 0x | 0x | 0x | 0x | 1.66x | 2.9x | 2.02x |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / EBIT | -0x | -0x | -0x | -0x | -0x | -3.21x | -1.93x | -1.87x |
| EV / FCF | -0x | -0x | -0x | -0x | -0x | 11.1x | -1.89x | -2x |
| FCF Yield | -15.3% | -22% | -13.4% | -35.3% | -81.5% | 9.05% | -52.9% | -49.9% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -3.37 | -1.95 | -0.15 | -1.07 | -1.18 | -0.6707 | -1.528 | -1.98 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 77.45 | 151.9 | 58.75 | 150 | 149.5 | 164.4 | 94.26 | 135 |
| EBITDA | -191.5 | -109.6 | -158.6 | - | - | - | - | - |
| EBIT 1 | -202.8 | -121.4 | -168.2 | -110.6 | -72.84 | -85.03 | -141.3 | -145.9 |
| Net income 1 | -202.1 | -119.8 | -9.058 | -66.97 | -74.62 | -18.31 | -127 | -167.8 |
| Net Debt | - | - | -229.8 | - | - | - | - | - |
| Reference price 2 | 16.050 | 6.710 | 9.620 | 3.250 | 1.610 | 4.300 | 4.300 | 4.300 |
| Nbr of stocks (in thousands) | 61,258 | 61,475 | 62,029 | 62,763 | 63,259 | 63,563 | - | - |
| Announcement Date | 24/02/22 | 15/03/23 | 07/03/24 | 20/03/25 | 09/03/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -6.41x | - | - | - | 273M | |
| 20.83x | 6.36x | 13.92x | 1.53% | 55.27B | |
| 32.72x | 8.17x | 25.61x | 0.05% | 54.15B | |
| -41.75x | 13.26x | -39.07x | -.--% | 23.11B | |
| -18.34x | 4.38x | -7.67x | -.--% | 23.22B | |
| 25.44x | 5.01x | 13.23x | -.--% | 20.33B | |
| 24.96x | 4.84x | 15.73x | -.--% | 17.91B | |
| -612.56x | 37.5x | -1557.05x | -.--% | 15.76B | |
| 45.31x | 18.35x | 47.24x | 0.08% | 15B | |
| 17.3x | 5.01x | 11.68x | -.--% | 13.82B | |
| Average | -51.25x | 11.43x | -164.04x | 0.18% | 23.88B | |
| Weighted average by Cap. | -26.13x | 9.75x | -92.41x | 0.37% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- MGNX Stock
- Valuation MacroGenics, Inc.
Select your edition
All financial news and data tailored to specific country editions
